our investment mission
To invest in companies which contribute to the creation of a more efficient and effective healthcare system and a better quality of life.
Wintop Capital is a registered fund manager with Monetary Authority of Singapore (MAS) founded by He Limin and Leong Mun Wai. Its flagship fund, Wintop Healthcare Fund, is focused primarily in the healthcare and pharmaceutical sectors.
A Balanced Portfolio
R & D Sector (40%)
Approximately 40% of capital to be deployed in medical technologies, bioscience and research and development intensive companies (“R&D Sector”) including the following sub-sectors:
Innovative medical devices and equipment
Healthcare supplements and natural remedies
- R & D SECTOR 40%
Medical service sector (60%)
Approximately 60% of capital to be deployed in production, operational and medical services companies (“Medical Services Sector”) including the following sub-sectors:
Pharmaceutical production and distribution
Hospital & clinics and pharmacy chains
Services that support the healthcare system
- MEDICAL SERVICE SECTOR 60%
ATTRACTIVE GROWTH OPPORTUNITIES
Global healthcare spending expected to accelerate at average rate of 5% growth p.a to $9.3 trillion* in 2018, approx 24% ($2.2 trillion) from Asia
* World industry outlook: Healthcare and pharmaceuticals, The Economist Intelligence Unit, May 2014
RISE OF ASIA
Asia is now the most exciting part of the world for healthcare businesses with rapidly ageing demographics and rising incomes across the region.
Affluence in Asia has led to surge in chronic ailments like diabetes, coronary diseases and others, resulting in a growing need in preventive and well-being healthcare.
Driven by the need to control cost and to provide better coverage, the healthcare system is undergoing radical reforms which provide abundant opportunities for innovation.
Healthcare investments range from defensive and mature cash generating assets (e.g. clinic chains & pharmacies) to small cap biotech or drug discovery companies that potentially offer multi-bagger returns.
CROSS BORDER INTEREST
Asian healthcare companies are increasingly seeking to expand across the region to build scale and scope of operations.